Glaucoma is a multifactorial spectrum of diseases in which progressive optic nerve damage leading to blindness occurs with raised intraocular pressure as the main risk factor. The outfl ow of fl uids through the trabecular meshwork decreases when the iris moves forward and comes into contact with it. This condition is called "angle closure" and can lead to glaucoma damage if intraocular pressure remains suffi ciently raised. When no other cause besides anatomical predisposition is present for the iridotrabecular contact, the condition is classifi ed as primary angle closure, and if glaucomatous optic neuropathy is present it is classifi ed as primary angle-closure glaucoma. The reported prevalence varies because of heterogeneity in defi nitions of primary angle-closure glaucoma and methods of angle assessment used in diff erent surveys. 1 Even more common than primary angle closure and primary angle-closure glaucoma is primary open-angle glaucoma. These three disorders have similarities, such as increasing prevalence after improvement, readily equalled by patients not so mobilised in the weeks after hospital discharge.
Far less is known about these later eff ects of early mobilisation, whether provided by an additional physical therapist or by more eff ective coordination and communication of existing resources. Regrettably, the International Early SOMS-guided Mobilisation Research Initiative achieved only 42% (84 of 200 patients) follow-up at 3 months. Such low fi gures at followup are not uncommon in ICU RCTs, although not universal. 6 A full endorsement of early mobilisation must wait for more data, even as many pragmatically attempt early mobilisation based on the hope that its eff ects on trajectory are durable. Large trials 7 of mobilisation in other patient groups provide caution to making assumptions about its long-term benefi t.
The future of early mobilisation research must move beyond the ICU and must include randomised tests of the hypothesis that early mobilisation provides enduring improvements for patients. Additionally, future research must go beyond the question of no mobilisation or some mobilisation. At some pointwhich will need more than 200 patients to be achievedthe diff erent strategies for mobilisation need to be compared. These diff erent strategies should include not only diff erent specifi c regimes of active exercise, but also diff erent approaches to integrate active exercise in the core interdisciplinary teamwork of the ICU. Use of these strategies will need use of all the tools of quality improvement, both RCTs and registries. Patients who are at particularly high risk for adverse outcomes of mobilisation need to be identifi ed, cognizant of the non-signifi cant diff erence in mortality seen in Schaller and colleagues' 4 and other RCTs. Furthermore, an understanding is needed of how early mobilisation can be integrated into coherent programmes of before ICU, in the ICU, and after ICU care to mitigate the postintensive care syndrome, maximising recovery for all critically ill patients.
The authors have proposed a large, international randomised clinical trial of early mobility to follow patients to well after hospital discharge. This proposal was submitted and under review before the invitation to write this Comment. This work does not necessarily represent the views of the US Government or the Department of Veterans Aff airs. age 50 years, but also striking diff erences, such as the increased frequency of primary angle closure in some ethnic groups. 2 Due to increased life expectancy and demographic expansion, the number of glaucoma cases worldwide is estimated to reach 76 million by 2020, of which 23 million will be primary angle-closure glaucoma. 3 The established initial treatment for primary angle closure and primary angle-closure glaucoma is laser iridotomy with eye drops to reduce intraocular pressure. In the past decade, lens extraction (both clear or with cataract) with intraocular lens implantation has gained popularity due to good results in series of patients with various primary types of angle closure based on diff erent defi nitions and anecdotal evidence. 4 Technological advances in surgical techniques have also improved the safety of phacoemulsifi cation in patients with glaucoma. Lens extraction either clear or with cataract to treat primary angle closure, judged on an individual basis, has also been recommended by guidelines. 4 Augusto Azuara-Blanco and colleagues 5 report in The Lancet the results of an international prospective randomised study comparing laser iridotomy with clear-lens extraction as the initial treatment of primary angle closure and primary angle-closure glaucoma. This is also the fi rst prospective randomised therapeutic trial in ophthalmology in which one of the primary outcome measures is patient reported, through quality-of-life questionnaires. The coprimary endpoints were patient-reported health status, intraocular pressure, and incremental costeff ectiveness ratio per quality-adjusted life-year gained 36 months after treatment. 419 patients were randomised and followed up for 3 years, of whom 208 were assigned to clear-lens extraction and 211 to laser iridotomy. 351 (84%) had complete data on health status and 366 (87%) on intraocular pressure. The results show a small but unquestionable advantage of primary clear-lens extraction over laser iridotomy for all measured outcomes. The mean health status score (0·87 [SD 0·12]) on the European Quality of Life-5 Dimensions (EQ-5D) questionnaire, was 0·052 higher (95% CI 0·015 to 0·088, p=0·005) and mean intraocular pressure (16·6 [SD 3·5] mm Hg) 1·18 mm Hg lower (95% CI -1·99 to -0·38, p=0·004) after clearlens extraction than after iridotomy. The incremental cost-eff ectiveness ratio was £14 284 for initial lens extraction versus standard care, although the costs were assessed only for the subset of patients treated in the UK and, therefore, are not conclusive for other settings.
This pragmatic trial is clinically relevant because it addresses a topic with widespread practical implications. Patients undergoing clear-lens extraction became emmetropic (fi nal refraction 0·08 [SD 0·95]), whereas those assigned to laser iridotomy remained hyperopic (0·92 [2·8] ). Uncorrected visual acuity, therefore, improved greatly for distance and near vision in the clear-lens extraction group only, which was associated with improvements in patientreported outcome questionnaires. How this purely refractive result aff ected the observed improvement in the clear-lens extraction group compared with the laser iridotomy group (a change in absolute terms of almost 6% for the EQ-5D, 7% for the Glaucoma Utility Index, and 2·58% for the National Eye Institute Visual Function Questionnaire-25) remains to be determined. The clinical relevance of the small diff erence between groups in intraocular pressure (1·18 mm Hg) is unclear since patients with advanced glaucoma damage were excluded from the study. The use of eye drops to lower intraocular pressure, however, was less in the clear-lens extraction group than in the laser iridotomy group (mean 0·4 [SD 0·8] vs 1·3 [1·0] ). This fi nding partly explains the small diff erence recorded for intraocular pressure. There was also a diff erence between groups
Photo Carlo E Traverso, Clinica Oculistica, DiNOGMI, Università di Genova, Genoa, Italy Eye with primary angle closure after clear-lens phacoemulsifi cation in the need for further surgery to control intraocular pressure (one patient in the clear-lens extraction group vs 24 patients in the laser iridotomy group); of the 24 patients in the laser iridotomy group who had further surgery, 16 (67%) underwent cataract surgery. However, the need for some cataract operations within 3 years is not surprising and this fi nding should not to be interpreted as an increased occurrence of an unfavourable outcome in the laser iridotomy group.
Cataract extraction by phacoemulsifi cation causes continued progressive endothelial cell loss, 6, 7 and increasing age is associated with decreasing endothelial cell counts. 8 The mean corneal endothelial cell loss after phacoemulsifi cation in patients whose eyes have shallow anterior chambers and short axial lengths-both features of primary angle closure-is around 19%.
9 Azuara-Blanco and colleagues 5 did not address corneal endothelial cell loss, possibly because such an assessment is not always part of the routine preoperative preparation for phacoemulsifi cation in most centres.
Primary angle closure and primary angle-closure glaucoma are very diff erent disorders, especially according to the defi nitions used by Azuara-Blanco and colleagues. They noted that their results are applicable only to patients with primary angle closure and intraocular pressure greater than 30 mm Hg-who represent a minority of patients with this disorder-or to those with primary angle-closure glaucoma without advanced damage, implying that these two groups would be expected to respond to treatment in a similar way. However, how generalisable the study's fi ndings are to other patients remains elusive.
Phacoemulsifi cation to treat primary angle closure can be technically challenging. The surgeons involved in Azuara-Blanco and colleagues' study were highly experienced. Training for routine cataract surgery might not provide the skills needed to reach consistently good results for phacoemulsifi cation clear-lens extraction in primary angle closure cases that would achieve the safety margin and avoid the few but potentially severe intraoperative complications reported in this study, and less experienced surgeons might incur more diffi culties and complications. Nevertheless, the study highlights the great advances made in phacoemulsifi cation techniques.
While not yet suffi cient to justify using clear-lens extraction to treat all patients with primary angle closure with or without glaucoma, the fi ndings of this trial could have positive implications for areas where angle closure is most prevalent, particularly east Asia, 3 or where health-care resources are scarce and patients might not have easy access to medications and monitoring.
A not yet proven potential additional benefi t with clear-lens extraction is that early intervention might prevent blindness due to primary angle-closure glaucoma. The fi ndings of Azuara-Blanco and colleagues underline the need for further eff orts to improve phenotyping of angle closure and for more randomised prospective therapeutic trials that include other subtypes of primary angle closure and assess the eff ects of laser iridotomy in eyes with narrow but not yet closed angles.
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